Latent transforming growth factor beta-binding protein 2

  • 文章类型: Journal Article
    背景:Weill-Marchesani综合征(WMS)是一种遗传性结缔组织疾病,在临床特征和遗传病因上具有实质性异质性,因此,定义完整的突变谱对于早期诊断至关重要。在这项研究中,我们报道了由潜伏转化生长因子β结合蛋白2(LTBP2)的新型单倍型突变引起的Weill-Marchesani样综合征(WMS样)向常染色体显性遗传的改变.
    方法:从广州招募了来自4代中国家庭的25名成员,其中9人被诊断患有WMS样疾病,九个是健康的,还有7人因为年龄小而临床状况“不确定”。所有成员都接受了详细的身体和眼部检查。全外显子组测序,桑格测序,和实时PCR用于鉴定和验证家族成员的致病突变。
    结果:基因测序揭示了与WMS样相关的相同LTBP2染色体上的新型单倍型突变,c.2657C>A/p。T886K在外显子16和外显子25-36的缺失。实时PCR和Sanger测序验证了临床诊断为WMS样的患者的两种突变,和一个“不确定”的孩子。在这些患者中,单倍型突变导致了扁桃体异位,身材矮小和肥胖。
    结论:我们的研究表明,WMS样突变可能与具有常染色体显性遗传的单倍型LTBP2突变有关。
    BACKGROUND: Weill-Marchesani syndrome (WMS) is a hereditary connective tissue disorder with substantial heterogeneity in clinical features and genetic etiology, so it is essential to define the full mutation spectrum for earlier diagnosis. In this study, we report Weill-Marchesani-like syndrome (WMS-like) change to autosomal dominance inheritance caused by novel haplotypic mutations in latent transforming growth factor beta-binding protein 2 (LTBP2).
    METHODS: Twenty-five members from a 4-generation Chinese family were recruited from Guangzhou, of whom nine were diagnosed with WMS-like disease, nine were healthy, and seven were of \"uncertain\" clinical status because of their young age. All members received detailed physical and ocular examinations. Whole-exome sequencing, Sanger sequencing, and real-time PCR were used to identify and verify the causative mutations in family members.
    RESULTS: Genetic sequencing revealed novel haplotypic mutations on the same LTBP2 chromosome associated with WMS-like, c. 2657C>A/p.T886K in exon 16 and deletion of exons 25-36. Real-time PCR and Sanger sequencing verified both mutations in patients with clinically diagnosed WMS-like, and in one \"uncertain\" child. In these patients, the haplotypic mutations led to ectopia lentis, short stature, and obesity.
    CONCLUSIONS: Our study revealed that WMS-like may be associated with haplotypic LTBP2 mutations with autosomal dominant inheritance.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:扩张型心肌病(DCM)是一种与心力衰竭相关的危及生命的疾病。细胞外基质蛋白在DCM的发病机制中具有重要作用。潜伏转化生长因子β结合蛋白2(LTBP-2),一种细胞外基质蛋白,尚未在DCM中进行调查。
    方法:首先,我们比较了131例接受心内膜心肌活检的DCM患者和44例年龄和性别匹配且无心脏异常的对照组的血浆LTBP-2水平.接下来,我们对心内膜活检标本进行了LTBP-2的免疫组织化学,并跟踪DCM患者的心室辅助装置(VAD)植入,心脏死亡,和全因死亡。
    结果:与对照组相比,DCM患者的血浆LTBP-2水平升高(P<0.001)。血浆LTBP-2水平与活检标本中心肌中的LTBP-2阳性分数呈正相关。当DCM患者根据LTBP-2水平分为两组时,Kaplan-Meier分析表明,高血浆LTBP-2患者与心脏死亡/VAD和全因死亡/VAD的发生率增加有关。此外,心肌LTBP-2阳性分数高的患者与这些不良结局的发生率增加相关.多变量Cox比例风险分析表明,血浆LTBP-2和心肌LTBP-2阳性分数与不良结局独立相关。
    结论:循环LTBP-2可作为预测不良结局的生物标志物,反映了细胞外基质LTBP-2在DCM心肌中的积累。
    Dilated cardiomyopathy (DCM) is a life-threatening disease related to heart failure. Extracellular matrix proteins have an important role in the pathogenesis of DCM. Latent transforming growth factor beta-binding protein 2 (LTBP-2), a type of extracellular matrix protein, has not been investigated in DCM.
    First, we compared plasma LTBP-2 levels in 131 patients with DCM who underwent endomyocardial biopsy and 44 controls who were matched for age and sex and had no cardiac abnormalities. Next, we performed immunohistochemistry for LTBP-2 on endomyocardial biopsy specimens and followed the DCM patients for ventricular assist device (VAD) implantation, cardiac death, and all-cause death.
    Patients with DCM had elevated plasma LTBP-2 levels compared with controls (P < 0.001). Plasma LTBP-2 levels were positively correlated with LTBP-2-positive fraction in the myocardium from the biopsy specimen. When patients with DCM were divided into 2 groups according to LTBP-2 levels, Kaplan-Meier analysis demonstrated that patients with high plasma LTBP-2 were associated with increased incidences of cardiac death/VAD and all-cause death/VAD. In addition, patients with high myocardial LTBP-2-positive fractions were associated with increased incidences of these adverse outcomes. Multivariable Cox proportional hazard analysis showed that plasma LTBP-2 and myocardial LTBP-2-positive fraction were independently associated with adverse outcomes.
    Circulating LTBP-2 can serve as a biomarker to predict adverse outcomes, reflecting extracellular matrix LTBP-2 accumulation in the myocardium in DCM.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号